Blackcat 13 the concerns you list above have all been resolved. As a matter of fact research points to possible benefits of iMSCs 0ver aMSC. Their ability to rejuvenate/repair DNA may make the safer than aMSCs. You are entitled to your opinion and look forward to debating further once the trial results are available, however the results obtained by CYP in the VERY SMALL TRIAL (n=15) are superior Day 28 OR 86% v MSB Adult <58% and 70% Paediatric. Based on this limited results CYP's iMSCs appear to be more potent.
Accordingly, the loss of the aging signature during iMSC derivation likely contributed to the advantageous features of iMSCs compared to primary MSCs. The observed fetal-like expression pattern of genes involved in DNA damage repair in iMSCs could be due to the involvement of this process in pluripotency induction. An alternative explanation could be that young or progenitor cells have a better capacity to repair DNA damage [71].
A rejuvenated state of processes involved in aging in iMSCs is furthermore likely as the epigenetic rejuvenation of MSCs through pluripotency induction has been described [13].
In summary, the current study shows that MSCs of fetal and aged background are not identical and MSCs generated from iPSCs (iMSCs) bear typical characteristics of native MSCs but more in common with fetal MSCs. The key finding from our study is the identification of a rejuvenation gene signature in iMSCs (irrespective of donor age) which also is present in pluripotent stem cells but not in the parental MSCs. Most important for regenerative medicine, iMSCs irrespective of initial age re-acquire a more similar secretome to that of fetal MSCs than aged MSCs. In conclusion, our findings show that the acquisition of a rejuvenated phenotype in iMSCs re-enforces the utility of the “iMSC concept” in regenerative medicine and cell replacement therapy in an ever increasing aging population.
MSB Price at posting:
$5.11 Sentiment: Buy Disclosure: Held
(20min delay)